Adrenergic responses are crucial for hypoglycemic recovery. Epinephrine increases glucose production, lipolysis, and peripheral insulin resistance as well as blood flow and glucose delivery. Sympathetic activation causes vasoconstriction and reduces glucose delivery. To determine the effects of ␣-and ␤-adrenergic activity on muscle glucose uptake during hypoglycemia, we studied forearm blood flow (FBF) (plethysmography), arteriovenous glucose difference (AV-diff), and forearm glucose uptake (FGU) during insulin infusion with 60 min of euglycemia followed by 60 min of hypoglycemia. Twelve healthy subjects (27 ؎ 5 years of age) were randomized to intravenous propranolol (IV PROP, 80 g/min), intravenous phentolamine (IV PHEN, 500 g/min), intra-arterial propranolol (IA PROP, 25 g/min), intra-arterial phentolamine (IA PHEN, 12 g/min per 100 ml forearm tissue), and saline (SAL). FBF increased during hypoglycemia with SAL (P < 0.001) but not with IA or IV PROP. FGU (P ‫؍‬ 0.015) and AV-diff (P ‫؍‬ 0.099) fell during hypoglycemia with IA PROP but not with IV PROP. FBF increased during hypoglycemia with IA and IV PHEN (P < 0.005). AV-diff fell during hypoglycemia with IA and IV PHEN (P < 0.01), but FGU was unchanged. Blood pressure fell (P < 0.001), and adrenergic and neuroglycopenic symptoms increased with IV PHEN (P < 0.01). Thus, systemic but not local propranolol prevents a decrease in forearm glucose extraction during hypoglycemia, suggesting that epinephrine increases peripheral muscular insulin resistance through systemic effects. ␣-Adrenergic activation inhibits vasodilation and helps maintain brain glucose delivery. Diabetes 51:734 -742, 2002 H ypoglycemia is the limiting factor in achieving good glycemic control in patients with type 1 diabetes. Discovering the physiologic mechanisms by which the body normally protects itself from hypoglycemia and how these mechanisms are altered in diabetes will increase our understanding of the pathophysiology and treatment of diabetes. We have demonstrated that during insulin-induced hypoglycemia, forearm blood flow (FBF) increases (1). The increase in flow augments glucose delivery and maintains normal glucose uptake despite a fall in glucose extraction. Local ␤-adrenergic blockade inhibits the vasodilation and leads to decreased forearm glucose uptake (FGU) during hypoglycemia, whereas local ␣-adrenergic blockade increases flow and increases FGU. In contrast to this, other authors have demonstrated that systemic combined ␣-and ␤-blockade and ␤-blockade alone lead to increased peripheral glucose uptake during hypoglycemia (2-6). The metabolic mechanisms by which increases in ␣-and/or ␤-adrenergic activity decrease peripheral glucose uptake during hypoglycemia are not clearly defined.
H
ypoglycemia is the limiting factor in achieving good glycemic control in patients with type 1 diabetes. Discovering the physiologic mechanisms by which the body normally protects itself from hypoglycemia and how these mechanisms are altered in diabetes will increase our understanding of the pathophysiology and treatment of diabetes. We have demonstrated that during insulin-induced hypoglycemia, forearm blood flow (FBF) increases (1) . The increase in flow augments glucose delivery and maintains normal glucose uptake despite a fall in glucose extraction. Local ␤-adrenergic blockade inhibits the vasodilation and leads to decreased forearm glucose uptake (FGU) during hypoglycemia, whereas local ␣-adrenergic blockade increases flow and increases FGU. In contrast to this, other authors have demonstrated that systemic combined ␣-and ␤-blockade and ␤-blockade alone lead to increased peripheral glucose uptake during hypoglycemia (2) (3) (4) (5) (6) . The metabolic mechanisms by which increases in ␣-and/or ␤-adrenergic activity decrease peripheral glucose uptake during hypoglycemia are not clearly defined.
Peripheral glucose uptake is dependent on two factors, fractional cellular glucose uptake and the amount of glucose delivered to the tissues (7, 8) . It is unclear whether the sympathetic activation that accompanies hypoglycemia is associated with decreased glucose transport or decreased glucose delivery or both. Nonoxidative glucose metabolism and muscle glycogen synthase activity decrease during hypoglycemia (9 -12) . These changes should decrease cellular glucose uptake. Conversely, glucose extraction in skeletal muscle may be enhanced during hypoglycemia because the glucose concentration in extracellular fluid decreases more than the plasma glucose concentration (13) . In support of this, Gore et al. (14) found that systemic infusions of epinephrine, cortisol, and glucagon increased leg glucose uptake and oxidation.
Increases in both ␣-and ␤-adrenergic activity may alter both glucose delivery and glucose extraction. The marked hemodynamic changes that happen during hypoglycemia with and without adrenergic blockade suggest that significant alterations in blood flow and vascular resistance occur. In healthy humans, heart rate increases during hypoglycemia while diastolic blood pressure falls and systolic blood pressure increases (15) (16) (17) (18) . Left ventricular ejection fraction also increases (18) . Epinephrine-induced, ␤-2-mediated vasodilation is a likely cause of many of these effects (19, 20) . During hypoglycemia with systemic ␤-blockade, diastolic pressure increases and there is a larger increase in systolic blood pressure (16 -18,21) . Heart rate and left ventricular ejection fraction do not change during hypoglycemia with ␤-blockade (18) . ␣-Blockade increases the fall in diastolic pressure and also decreases systolic pressure (18, 22) . ␣-Blockade has no effect on the hypoglycemic changes in heart rate or cardiac contractility (18) . In dogs, total peripheral vascular resistance decreases during hypoglycemia alone or with combined ␣-and ␤-blockade but increases during hypoglycemia with ␤-blockade alone (22) . The increase in peripheral vascular resistance and blood pressure during hypoglycemia with ␤-blockade suggest that the increased ␣-adrenergic vasoconstrictor activity during hypoglycemia is independent of epinephrine-induced vasodilation. The changes in blood flow during hypoglycemia may be associated with changes in tissue glucose delivery, depending on whether the change in flow affects capillary perfusion or arteriovenous shunting (23) .
Cellular fractional glucose extraction is determined by the plasma and tissue glucose concentrations and by the cell's ability to transport glucose. Epinephrine infusion causes a variety of changes in glucose utilization when given during euglycemic-hyperinsulinemic clamp (24) . Specifically, in healthy control subjects, insulin sensitivity and glucose's ability to stimulate its own disposal decrease (25) , and in patients with type 1 diabetes, insulin-mediated but not non-insulin-mediated glucose disposal falls during epinephrine infusion (26) . Intra-arterial infusions of epinephrine cause marked reductions of intra-arterial insulininduced FGU despite mild increases in FBF (27) .
The goal of this study was to distinguish between the local and systemic effects of hypoglycemic adrenergic counterregulation on FGU and metabolism in healthy male and female subjects.
of forearm tissue), and saline (SAL), as randomly assigned. This dose of IA PHEN decreases forearm vasoconstriction during norepinephrine infusion from 67 to 15% without affecting systemic blood pressure or heart rate (30) . The dose of IA PROP blocks isoproterenol induced vasodilation without systemic effects (C.A.S., unpublished data). The infusions were started 20 min before beginning insulin. The hyperinsulinemic clamp was then initiated and maintained for 120 min with 60 min of euglycemia followed by 60 min of hypoglycemia. Just before the clamp, at 60 min, and at 120 min, arterial and venous blood was drawn for measurement of plasma lactate and free fatty acid (FFA) concentrations; venous blood was drawn for measurement of plasma catecholamines.
Subjects verbally completed a symptom questionnaire at the end of the baseline period before the clamp and just before the completion of euglycemia and hypoglycemia (31) . Symptoms were assigned as adrenergic, neuroglycopenic, or cholinergic as assigned by Towler et al. (32) . Data analysis. Electrocardiogram, FBF, respirations, and arterial pressure were measured simultaneously with a computerized data acquisition system (MacLab; AD Instruments, Grand Junction, CO) and Macintosh Quadra 950 Computer (Apple Computer, Cupentino, CA). FBF was measured as milliliters per minute per 100 ml of forearm volume. FGU was measured using the Frick
Assays. Plasma glucose was measured immediately using one of two YSI 2300 Stat Glucose Analyzers (Yellow Springs Instruments, Yellow Springs, OH). Arterial and venous samples were alternately measured on each machine; lactate was measured on one of the analyzers that also had a lactate probe. Catecholamines were determined by adding 1 ml centrifuged plasma to a glass extraction vial containing 20 mg acid-washed alumina (Bioanalytical Systems, West Lafayette, IN), 20 l of a solution containing the internal standard (3,4 dihydroxy-benzylamine in 0.01 N HCl), 1 ml phosphate buffer (0.l mol/l [pH 7.0] plus 0.05 mol/l EDTA) and l ml Tris buffer (1.5 mol/l [pH 8.6] plus 0.05 mol/l NaEDTA). After immediate gentle shaking for 10 min, the alumina was allowed to settle and the supernatant was aspirated to waste. After two washes with water, catecholamines were eluted from the alumina with 200 l of 4% acetic acid. After centrifugal microfiltration using individual 0.2-m regenerated cellulose membranes, each sample was chromatographed on a Catecholamine Column (Keystone Scientific, Bellefonte, PA; 3-particle size, 100 ϫ 4.6 mm, reverse-phase, C-18 ODS, 10% carbon, end-capped) using a mobile phase of 75 mmol/l monobasic sodium phosphate, 0.12 mmol/l NaEDTA, 10 mmol/l citric acid, 15% acetonitrile, 10% methanol, and 1.5 mmol/l sodium dodecyl sulfate as the ion pairing agent. The catecholamines were detected with a Coulochem II Dual Potentiostat Electrochemical Detector (ESA, Chelmsford, MA). Peaks were quantified on a Shimadzu CR5-A integrator. A standard curve for extracted catecholamines (0, 125, 250, 500, 750, 1,000, 1,500, and 2,000 pg of each catecholamine) was prepared using "blank" human plasma (dialyzed to remove endogenous catecholamines), and linear regression analysis was used to determine sample plasma concentrations. The assay has interassay and intra-assay coefficients of variation of 3.4 and 3.1%, respectively, and a lower limit of detection of 25 pg/ml. Plasma FFAs were measured by an enzymatic colorimetric method (Wako NEFA C Kit; Biochemical Diagnostics, Edgewood, NY). The low-, middle-, and high-range coefficients of variation were 2.7, 1.1, and 1.1%, respectively. Plasma insulin was measured by double-antibody radioimmunoassay with interassay and intraassay coefficients of 9.4 and 5.3%, respectively. Statistical analyses. Differences in measured parameters were determined using a one-way repeated measures ANOVA of all data. Planned contrasts were used to determine differences between groups and for changes between the end of euglycemia and hypoglycemia. Multiple linear regression analysis was used to assess correlations between subjects. Statistical significance was defined as P Ͻ 0.05. Results are reported as mean Ϯ SE.
RESULTS
Glucose and insulin. Arterial plasma glucose levels did not differ at any time between the studies. At the end of hypoglycemia, mean arterial plasma glucose levels were 2.7 Ϯ 0.1 mmol/l for SAL, 2.8 Ϯ 0.1 mmol/l for IA PROP, 2.9 Ϯ 0.1 mmol/l for IV PROP, 2.8 Ϯ 0.1 mmol/l for IA PHEN, and 3.0 Ϯ 0.1 mmol/l for IV PHEN. Venous plasma insulin levels did not differ at any time among the three studies (Fig. 1) . Hemodynamics. ANOVA revealed that heart rate varied over time (F 14 -462 ϭ 6.13; P Ͻ 0.001) and that there were differences between studies (time by study interaction, F 56 -462 ϭ 6.33; P Ͻ 0.001). IA PROP, IV PROP, IA PHEN, and IV PHEN alone did not alter heart rate. Heart rate did not change during euglycemic hyperinsulinemia with SAL, IA PROP, or IV PROP but was increased at the end of 60 min of euglycemic hyperinsulinemia with both IA PHEN (P ϭ 0.003) and IV PHEN (P Ͻ 0.001). Heart rate tended to fall during hypoglycemia with IA PROP (P ϭ 0.057) and IV PROP (P ϭ 0.072) but did not change with SAL. Heart rate was increased further at the end of hypoglycemia for IV PHEN (P Ͻ 0.001; Table 1 ).
ANOVA also revealed that mean arterial pressure varied over time (F 14 -462 ϭ 5.01; P Ͻ 0.001) and that there were differences between studies (time by study interaction, F 56 -462 ϭ 8.31; P Ͻ 0.001). During the initial infusion alone period, mean arterial pressure fell with IV PHEN (P Ͻ 0.001). No additional changes occurred during the first 60 min with euglycemic hyperinsulinemia during any session. Mean arterial pressure significantly increased during hypoglycemia with both IA PROP and IV PROP (P ϭ 0.001 and P ϭ 0.003, respectively) but tended to fall with SAL (P ϭ 0.077). Mean arterial pressure fell significantly at the end of hypoglycemia with both IA PHEN and IV PHEN studies (P Ͻ 0.001).
FBF (Fig. 2) significantly changed with time (F 12-462 ϭ 33.8; P Ͻ 0.001), and these changes differed between sessions (time by session interaction, F 56 -462 ϭ 12.0; P Ͻ 0.001). FBF did not change with SAL, IV PROP, or IV PHEN but decreased 20 min after starting IA PROP (P ϭ 0.009) and increased after 20 min of IA PHEN (P Ͻ 0.001). FBF did not change during 60-min euglycemic insulin infusion with SAL, IA PROP, or IV PROP but increased at the end of euglycemic hyperinsulinemia with IA PHEN (P ϭ 0.049) and with IV PHEN (P ϭ 0.048). FBF at the end of hypoglycemia was increased compared with the end of euglycemia with SAL (P Ͻ 0.001), IA PHEN (P Ͻ 0.001), and IV PHEN (P ϭ 0.003). There was no change during hypoglycemia with IA PROP or IV PROP. Glucose extraction and utilization. AV-diff (Fig. 3 ) also changed significantly with time (F 12-462 ϭ 31.3; P Ͻ 0.001), and these changes differed between sessions (time by session interaction, F 56 -462 ϭ 1.43; P ϭ 0.026). AV-diff did not change with any of the infusions alone and increased, as expected, during euglycemic insulin infusion with SAL (P ϭ 0.010), IA PROP (P ϭ 0.005), IV PROP (P ϭ 0.001), and IV PHEN (P ϭ 0.014). The increase in AV-diff during euglycemic hyperinsulinemia with IA PHEN did not quite reach statistical significance (P ϭ 0.060). At the end of hypoglycemia (120 min), AV-diff was lower than at the end of euglycemia (60 min; P Ͻ 0.001) during SAL, IA PHEN (P ϭ 0.007), and IV PHEN (P ϭ 0.006). AV-diff at the end of hypoglycemia and euglycemia tended to be different with IA PROP (P ϭ 0.084) but not with IV PROP. changes over time between sessions were not different. Baseline FGU was not altered by any of the infusions. Again, as expected, FGU increased during 60 min of euglycemic insulin infusion with IA SAL (P ϭ 0.051), IA PROP (P ϭ 0.018), IV PROP (P ϭ 0.022), IA PHEN (P ϭ 0.001), and IV PHEN (P ϭ 0.007). FGU at the end of hypoglycemia with SAL tended to fall (P ϭ 0.079) as a result of the fall in glucose extraction, but this was counterbalanced by an increase in glucose delivery. The nonsignificant decreases in FBF and AV-diff during hypoglycemia with IA PROP led to a significant decrease in FGU at the end of hypoglycemia (P ϭ 0.015). FGU was unchanged at the end of hypoglycemia with IV PROP because glucose extraction was unchanged and glucose delivery fell only slightly. FGU at the end of hypoglycemia was not different from that at the end of euglycemia for IA PHEN and IV PHEN because the decreases in glucose extraction were offset by the increase in glucose delivery (Fig. 4) .
FFAs and lactate.
Arterial plasma FFA levels changed with time (time by session interaction, F 2-64 ϭ 46.8; P Ͻ 0.001), and the changes differed between sessions (F 8 -64 ϭ 3.49; P ϭ 0.002). Arterial plasma FFA levels fell during euglycemic hyperinsulinemia for all five sessions and fell further during hypoglycemia with IV PROP (P ϭ 0.027) but increased during hypoglycemia with IA PHEN (P ϭ 0.032) and IV PHEN (P ϭ 0.008). No change was seen during hypoglycemia with IA PROP or SAL. Arterial FFA (AFFA) levels at the end of hypoglycemia with IV PROP were lower than after IA PROP (P ϭ 0.022), SAL (P ϭ 0.044), or IV PHEN (P ϭ 0.003), and levels were higher at the end of hypoglycemia with IV PHEN than with SAL (P ϭ 0.035). Net forearm fat uptake did not change during euglycemia hyperinsulinemia or with hypoglycemia and did not differ between subjects (Table 2) . Forearm lactate production increased during euglycemic hyperinsulinemia during all sessions (P Ͻ 0.02); it did not increase further during hypoglycemia with IA PROP, IV PROP, or IV PHEN but did with SAL (P ϭ 0.005) and IA PHEN (P Ͻ 0.001).
Plasma epinephrine increased during hypoglycemia with all sessions (P Ͻ 0.05). Levels were significantly higher at the end of hypoglycemia with IA PROP and IV PROP than with SAL. Plasma norepinephrine levels increase during euglycemic hyperinsulinemic clamp with IA PHEN and IV PHEN (P Ͻ 0.05) and during hypoglycemia for the other three studies. Determinants of glucose extraction. For all studies, AV-diff at the end of hypoglycemia was negatively correlated with both AFFA level (AFFA, r ϭ Ϫ0.41, P ϭ 0.012; Symptoms. Adrenergic symptom scores (Fig. 6) significantly increased from euglycemia to hypoglycemia with IV PHEN (P Ͻ 0.001) but not with IV PROP or SAL. Adrenergic symptom scores at the end of hypoglycemia were higher with IV PHEN than with IV PROP (P ϭ 0.003) or SAL (P ϭ 0.009). Neuroglycopenic symptoms followed a similar pattern with a significant increase only during hypoglycemia with IV PHEN (P ϭ 0.001). Again, neuroglycopenic symptom scores with IV PHEN were higher at the end of hypoglycemia than with IV PROP (P ϭ 0.031) or SAL (P ϭ 0.008). The latter two did not differ. Cholinergic symptoms increased during hypoglycemia with IV PHEN (P Ͻ 0.001) and IV PROP (P Ͻ 0.001) but not during SAL. Cholinergic symptoms at the end of hypoglycemia tended to be higher with IV PHEN than with SAL (P ϭ 0.054). Cholinergic symptoms at the end of hypoglycemia with IV PROP were not different from the other studies.
DISCUSSION
Epinephrine induces peripheral insulin resistance and thus decreases peripheral glucose uptake for up to 6 h after short-term epinephrine infusion (33, 34) . One possible mechanism for this is through increased FFAs, which provide an alternative fuel and competitively inhibit glucose uptake (35, 36) . Glucose infusion rates during insulin clamps are inversely related to fat oxidation rates in control subjects (37) and patients with type 2 diabetes (38) . The increase in FFAs provides an alternative fuel to glucose for muscle utilization and competitively inhibits muscle glucose utilization (34, 37) . FFAs have also been shown to alter cell membrane glucose transport (39) .
Epinephrine may also have a direct muscular action (40, 41) . Intra-arterial epinephrine infusions have been shown to decrease FGU (27) through several possible mechanisms. These include decreased intrinsic activity of GLUT4 glucose transporters at the cell membrane (10) and increased muscle glycogenolysis and intracellular glucose-6-phosphate, which inhibits cellular glucose transport (42, 43) .
Our results demonstrate that during hypoglycemia, the main local effect of increased ␤-adrenergic activity and thus epinephrine is to increase blood flow and glucose delivery to the tissues. In normal situations, this vasodilatory effect is partially balanced by an increase in vasoconstrictor ␣-adrenergic activity as indicated by the differences in FBF between hypoglycemia with SAL and hypoglycemia with IA PHEN. Because glucose extraction decreased during hypoglycemia with IA PROP and was unchanged during hypoglycemia with IV PROP, ␤-adrenergic system activation during hypoglycemia primarily causes muscular insulin resistance through its systemic effects. The differences in AFFA levels between IA PROP and IV PROP at the end of the two studies and the correlation between AFFA levels and AV-diff support the hypothesis that the systemic effect is exerted through increased lipolysis. Last, the lack of relationship between forearm FFA and glucose uptake suggests that the effect is mediated independent of fat utilization and is likely related to FFAs altering membrane glucose transport (39) .
Microdialysis studies have indicated that epinephrine has a dual effect on lipolysis in subcutaneous tissues. It stimulates lipolysis primarily through ␤-adrenergic recep- tors and inhibits lipolysis primarily through ␣2-adrenergic receptors (44,45). Our results during hypoglycemia agree with these findings because AFFA levels fell during hypoglycemia with IV PROP but increased dramatically during hypoglycemia with IV PHEN and unopposed ␤-adrenergic activity. From our data, there seems to be little difference between the local and systemic effects of ␣-adrenergic activation on muscular glucose utilization because the pattern changes in FBF, AV-diff, and FGU were very similar. This cannot be said conclusively because the intra-arterial phentolamine, at the dose used, clearly had a systemic effect and local effect. This is demonstrated by the similarities in FFAs during hypoglycemia with IA PHEN and IV PHEN. The differences in heart rate and blood pressure indicate that the systemic effect was less with IA PHEN than with IV PHEN. Conversely, the local effect of IV PHEN was less than that of IA PHEN because FBF was greater with the latter. It is clear, however, that the main effect of ␣-adrenergic activation during hypoglycemia is to prevent excess vasodilation. The increased glucose delivery during hypoglycemia with ␣-adrenergic blockade is offset by a decrease in glucose extraction. This decrease likely is a compensatory response to the increases in flow and is due to increased AFFA concentrations.
Of particular interest during ␣-adrenergic blockade is that there is a marked increase in adrenergic and neuroglycopenic symptoms during hypoglycemia with IV PHEN compared with SAL or IA PROP. Although our data allow us to speculate only regarding the cause, one possibility is that the increase is due to decreased glucose delivery to the brain secondary to the marked fall in blood pressure. This effect thus would be similar to that of caffeine, which has been shown to decrease middle cerebral artery flow velocity and increase autonomic and neuroglycopenic symptoms during hypoglycemia in patients with type 1 diabetes (46) . This study also indicated that caffeine increased the epinephrine response to hypoglycemia. We did not see differences in epinephrine response between hypoglycemia with IA PHEN and SAL; however, the changes in catecholamine in our study were clearly altered by the blocking agents and thus do not reflect what might happen with decreased brain blood flow during hypoglycemia under other conditions. Thus, the ␣-adrenergic inhibition of excessive vasodilation maintains normal blood pressure and likely helps sustain brain blood flow. The increased cholinergic symptoms with both IV PHEN and IV PROP may be due to unopposed cholinergic activity.
The major limitation of our study involves the use of venous occlusion plethysmography for measurement of FBF. With this technique, direct comparisons between different sessions are not appropriate. Because FBF was used in determining FGU, the variability in FBF likely explains the lack of significant differences between sessions. Comparisons within sessions are valid, however (28) , and thus the comparison of responses between sessions is valid.
These results help discern some of the complex local and systemic interactions by which sympathetic activation protects the body and brain from the adverse effects of hypoglycemia. ␤-Adrenergic activation decreases muscular glucose extraction primarily by increasing FFAs, whereas ␣-adrenergic activation prevents excessive ␤-induced vasodilation.
